Skip to main content
SpringerLink
Log in

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We aimed to compare two different salvage treatment strategies for relapsed high-grade glioma (HGG) patients by means of a new prognostic model. A simplified version of the so-called HGG-Immuno RPA model estimates the prognosis of relapsed HGG patients and distinguishes three different prognostic classes (I = good, II = intermediate, III = poor). The model has been constructed with a cohort of 117 patients whose salvage treatment consisted of re-operation followed by dendritic cell vaccination (ReOP + DCV). However, using only the predictors histology, age and performance status, the simplified HGG-Immuno RPA model is basically independent from treatment. In the present study we applied the simplified model to the cohort used to construct the original HGG-Immuno RPA model and another cohort of 165 patients who underwent re-irradiation (ReRT) at relapse. Then, we compared the outcomes achieved by the two different salvage treatments in each prognostic class. The model predicted good, intermediate and poor prognosis for 11, 31 and 75 patients of the ReOP + DCV cohort and for 20, 39 and 106 patients of the ReRT cohort, respectively. Neither of the two strategies was superior to the other. In the groups with good, intermediate and poor prognosis 12-months survival rates were 73, 59 and 25 % after ReOP + DCV and 72, 36 and 23 % after ReRT, respectively. Being easy to handle and independent from treatment, the aforementioned model is useful for therapeutic decisions. ReRT and ReOP + DVC seem to be equally effective. The choice of salvage treatment should be based on the expected side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balana C, Gil M, Gallardo A, Murata P, Barnadas A (2014) Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. J Neurooncol 116(2):413–419. doi:10.1007/s11060-013-1316-y

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Committee ACJG (2014) The role of cytotoxic chemotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):501–555. doi:10.1007/s11060-013-1338-5

    Article  CAS  PubMed  Google Scholar 

  3. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC, Committee ACJG (2014) The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):557–599. doi:10.1007/s11060-013-1339-4

    Article  CAS  PubMed  Google Scholar 

  4. Quick J, Gessler F, Dutzmann S, Hattingen E, Harter PN, Weise LM, Franz K, Seifert V, Senft C (2014) Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 117(2):365–372. doi:10.1007/s11060-014-1397-2

    Article  CAS  PubMed  Google Scholar 

  5. Ryken TC, Kalkanis SN, Buatti JM, Olson JJ, Committee ACJG (2014) The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):479–488. doi:10.1007/s11060-013-1336-7

    Article  PubMed  Google Scholar 

  6. Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ, Committee ACJG (2014) The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):489–499. doi:10.1007/s11060-013-1337-6

    Article  CAS  PubMed  Google Scholar 

  7. De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, van Loon J, Goffin J, Van Gool S (2012) Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother 61(11):2105–2112. doi:10.1007/s00262-012-1271-z

    Article  PubMed  Google Scholar 

  8. Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK (1994) Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat 32(1):105–112

    Article  CAS  PubMed  Google Scholar 

  9. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14(10):3098–3104. doi:10.1158/1078-0432.CCR-07-4875

    Article  PubMed  Google Scholar 

  10. Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185(2):113–119. doi:10.1007/s00066-009-1969-9

    Article  PubMed  Google Scholar 

  11. Hundsberger T, Brugge D, Putora PM, Weder P, Weber J, Plasswilm L (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 112(1):133–139. doi:10.1007/s11060-013-1044-3

    Article  CAS  PubMed  Google Scholar 

  12. Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann KT, Combs SE, von Bueren AO, Kortmann RD, Muller K (2013) Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 8(1):161. doi:10.1186/1748-717X-8-161

    Article  PubMed Central  PubMed  Google Scholar 

  13. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4):453–473

    Article  CAS  PubMed  Google Scholar 

  14. Royston P, Altman DG (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 13:33. doi:10.1186/1471-2288-13-33

    Article  PubMed Central  PubMed  Google Scholar 

  15. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346

    Article  CAS  PubMed  Google Scholar 

  16. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379. doi:10.1016/S1470-2045(13)70168-2

    Article  CAS  PubMed  Google Scholar 

  17. Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma: are we there yet? Neuro-Oncol 15(1):4–27. doi:10.1093/neuonc/nos273

    Article  PubMed Central  PubMed  Google Scholar 

  18. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98(1):1–14. doi:10.1016/j.radonc.2010.11.006

    Article  PubMed  Google Scholar 

  19. Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, Lim M, Brem H, Quinones-Hinojosa A (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–820. doi:10.3171/2012.9.JNS1277

    Article  PubMed Central  PubMed  Google Scholar 

  20. Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT (2014) Vaccine therapies for patients with glioblastoma. J Neurooncol 119(3):531–546. doi:10.1007/s11060-014-1502-6

    Article  CAS  PubMed  Google Scholar 

  21. Shah AH, Bregy A, Heros DO, Komotar RJ, Goldberg J (2013) Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol. Neurosurgery 73(5):863–867. doi:10.1227/NEU.0000000000000107

    Article  PubMed  Google Scholar 

  22. Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE (2014) A phase II, randomized, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 20(24):6304–6313. doi:10.1158/1078-0432.CCR-14-0951-T

    Article  CAS  PubMed  Google Scholar 

  23. NCCN Guidelines Version 1 (2013) Anaplastic gliomas/glioblastoma. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

Download references

Conflict of interest

The authors indicated no potential conflicts of interest.

Ethical standards

This manuscript is in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent amendments.

Author information

Author notes

    Authors and Affiliations

    1. Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany

      Klaus Müller, Sophie Pietschmann & Rolf-Dieter Kortmann

    2. Department of Radiation Oncology, Hospital Chemnitz, Bürgerstraße 2, 09113, Chemnitz, Germany

      Klaus Müller & Gunther Klautke

    3. Department of Radiation Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

      Guido Henke

    4. Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany

      Guido Henke

    5. Laboratory of Experimental Immunology, Catholic University Leuven, Leuven, Belgium

      Stefaan van Gool & Steven De Vleeschouwer

    6. Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Göttingen, Germany

      André O. von Bueren

    7. Department of Radiation Oncology (MAASTRO), GROW (School for Oncology & Developmental Biology), University of Maastricht Medical Center, Maastricht, The Netherlands

      Inge Compter & Brigitta G. Baumert

    8. Division of Pediatric Oncology, Hematology and Hemostaseology, Department of Woman’s and Children’s Health, University Hospital Leipzig, Leipzig, Germany

      Carsten Friedrich

    9. Department of Radiation Oncology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany

      Christiane Matuschek

    10. Departments of Neurology and Haematology/Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

      Thomas Hundsberger

    11. Clinical Cooperation Unit Neurooncology, Department of Radiation Oncology, MediClin Robert Janker Clinic & University of Bonn Medical Center, Bonn, Germany

      Brigitta G. Baumert

    Authors
    1. Klaus Müller
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Guido Henke
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Sophie Pietschmann
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Stefaan van Gool
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Steven De Vleeschouwer
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. André O. von Bueren
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Inge Compter
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Carsten Friedrich
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Christiane Matuschek
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Gunther Klautke
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Rolf-Dieter Kortmann
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Thomas Hundsberger
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Brigitta G. Baumert
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Klaus Müller.

    Additional information

    Thomas Hundsberger and Brigitta G. Baumert have contributed equally to this article.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Müller, K., Henke, G., Pietschmann, S. et al. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. J Neurooncol 124, 325–332 (2015). https://doi.org/10.1007/s11060-015-1844-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11060-015-1844-8

    Keywords

    Search

    Navigation